ZP3022

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Body Weight (Weight, Body) 11/12/2020 - "Though glucagon-like peptide 1 receptor (GLP-1R)/cholecystokinin 2 receptor (CCK-2R) dual agonist ZP3022 potently increases β-cell mass and improves glycemic control in diabetic db/db mice, the in vivo half-life (t1/2) is short, and its body weight reducing activity is limited. " 01/01/2022 - "In DIO mice, the metabolic benefits of xGLP-1/GCG/gastrin, such as reduction of body weight and hepatic lipid contents were significantly better than those of the peptide ZP3022 (GLP-1/CCK-2 dual agonist) and liraglutide. "
2.	Type 2 Diabetes Mellitus (MODY) 07/01/2015 - "These data suggest that ZP3022 may have therapeutic potential in the prevention/delay of beta cell dysfunction in type 2 diabetes."

1.	Glucagon-Like Peptide 1 (GLP 1)
2.	Cholecystokinin B Receptor
3.	Peptides (Polypeptides)
4.	Lipids
5.	Gastrins
6.	Liraglutide
7.	Glucagon-Like Peptide-1 Receptor

1.	Glycemic Control